WITH WEIGHT LOSS DRUGS IN HIGH DEMAND – ELI LILLY IS SIGNIFICANTLY LOWERING THE PRICE OF ITS DRUG ZEPBOUND IN A MOVE TO MAKE IT EASIER FOR PEOPLE TO GET THEIR HANDS ON IT… BUT THERE IS A CATCH. 

THE DRUGMAKER IS DROPPING THE PRICES FOR ITS TWO LOWEST DOSES OF THE WEIGHT LOSS MEDICATION… BUT IT WILL ONLY COME IN SINGLE-DOSE VIALS THAT YOU’LL HAVE TO LOAD INTO A SYRINGE YOURSELF.

ZEPBOUND AND OTHER SIMILAR WEIGHT LOSS DRUGS USUALLY COME IN SELF-CONTAINED INJECTOR PENS. 

UNDER THE NEW PRICING PLAN, A MONTH’S SUPPLY OF THE LOWEST DOSE –  POINT 5 MILLIGRAMS – WILL COST 399 DOLLARS… 

WHILE A MONTH’S SUPPLY OF THE 5 MG DOSE WILL COST 549 DOLLARS. 

THAT’S A BIG DIFFERENCE FROM A MONTHLY LIST PRICE OF MORE THAN A THOUSAND DOLLARS REGARDLESS OF THE DOSAGE. 

USE OF TIRZEPATIDE – THE ACTIVE INGREDIENT IN ZEPBOUND – TO LOSE WEIGHT HAS SKYROCKETED IN POPULARITY… LEADING TO SHORTAGES… AND LEADING SOME PEOPLE WHO CAN’T GET A PRESCRIPTION OR WHOSE INSURANCE DOESN’T COVER IT TO USE VERSIONS MADE BY COMPOUNDING PHARMACIES, WHICH CAN BE DANGEROUS. 

THE NEW SINGLE-DOSE VIALS WILL *ONLY* BE AVAILABLE THROUGH THE COMPANY’S TELEHEALTH PLATFORM – LILLY DIRECT – TO THOSE WHO PAY OUT OF POCKET.